AvenCell

Healthcare & Life Sciences

Recent Finacing

Series B

Recent Raise

$112M

AvenCell Therapeutics, Inc. develops a Universal Switchable CAR-T cell therapy platform for treating hematologic malignancies and autoimmune diseases.

Total Funding

$112M

Headquarters

Watertown, USA

Founded

2021

Website

avencell.com

Focus Areas

Cell therapy

CAR-T

Hematologic malignancies

Autoimmune diseases

Clinical-stage

Universal switchable platform

Investors